Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR alterations
Express Pharma
MAY 5, 2024
Phase 1 trial shows 90 per cent recurrence-free survival and 90 per cent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively Janssen-Cilag International NV, a Johnson & Johnson company, recently updated results from an open-label, multicentre, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, i
Let's personalize your content